Cocrystal Pharma (COCP)
(Delayed Data from NSDQ)
$1.40 USD
-0.10 (-6.67%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $1.41 +0.01 (0.71%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cocrystal Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 2 | 7 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 2 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 39 | 14 | 12 | 55 |
Income After Depreciation & Amortization | 0 | -39 | -14 | -10 | -48 |
Non-Operating Income | NA | 0 | 0 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -39 | -14 | -10 | -48 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -39 | -14 | -10 | -48 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -39 | -14 | -10 | -48 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -19 | -14 | -9 | -2 |
Depreciation & Amortization (Cash Flow) | NA | 19 | 0 | 0 | 46 |
Income After Depreciation & Amortization | 0 | -39 | -14 | -10 | -48 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 8.14 | 7.36 | 4.60 | 2.65 |
Diluted EPS Before Non-Recurring Items | NA | -2.23 | -1.92 | -2.04 | -0.72 |
Diluted Net EPS (GAAP) | NA | -4.77 | -1.92 | -2.04 | -18.13 |
Fiscal Year end for Cocrystal Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.44 | 4.34 | 5.11 | 4.51 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -4.44 | -4.34 | -5.11 | -4.51 |
Non-Operating Income | NA | -0.04 | 0.17 | -0.08 | 0.00 |
Interest Expense | NA | -0.32 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -4.17 | -4.17 | -5.19 | -4.50 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -4.17 | -4.17 | -5.19 | -4.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -4.17 | -4.17 | -5.19 | -4.50 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | NA | 10.15 | 10.07 | 8.14 | 8.14 |
Diluted EPS Before Non-Recurring Items | NA | -0.41 | -0.50 | -0.64 | -0.55 |
Diluted Net EPS (GAAP) | NA | -0.41 | -0.41 | -0.64 | -0.59 |